Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17536

    +

    P2.02-043 - Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC (ID 4640)

    14:30 - 14:30  |  Author(s): H. Hu
    • Abstract
    • Slides

    Background:
    Tumor-derived autophagosomes (DRibbles®) are a novel cancer immunotherapy providing cross-protection against related tumors and efficacy against established tumors preclinically. We hypothesize efficacy is via presentation of short-lived proteins (SLiPs) and defective ribosomal products (DRiPs) normally not cross-presented by antigen-presenting cells (APCs). DRibble DPV-001 vaccine packages putative cancer antigens, including 13 from the NCI priority list and TLR 2, 3, 4, 7 and 9 agonist activity into microvesicles, with molecules targeting DRibbles to CLEC9A+ APCs. NSCLC overexpresses an average of 176 proteins found in DPV-001. Many of these antigens have single amino acid variants that may serve as immunogenic mimetopes, or altered peptide ligands.
    
    Methods:
    Pts completed curative-intent therapy for stage III NSCLC. Treatment: Induction cyclophosphamide; DPV-001 vaccine every 3 weeks x7; then every 6-weeks x4. Randomization was to DPV-001 alone (Arm A), or with an adjuvant; imiquimod (Arm B), or GM-CSF (Arm C). Peripheral blood mononuclear cells and serum were collected at baseline and at each vaccination. Serum was analyzed for >15 fold increased antibody responses to >9000 human proteins (ProtoArray) from baseline to week 12. 11 pts were to be randomized to each arm, with 15 more enrolled on the arm with the greatest number of >15 fold antibody responses.
    
    Results:
    13 pts were enrolled into the randomized phase I portion, when enrollment was stopped due to end of grant term. Arm A: 5 pts; B: 4; C: 4. Median Age: 60 (range 45-76); Male/Female: 6/7. Median vaccines administered: 6 (range 3-11); 2 pts still receiving treatment. Reasons for discontinuation: Disease progression (6); 2 toxicity (1 grade 3 dyspnea possibly related, 1 recurrent grade 1 migratory rash with pruritis, related); 1 noncompliance; 1 for elective surgery (unrelated). Other toxicities were grade 1/2; 1 additional grade 3 fatigue (possibly related). Analysis was limited due to small sample size. Median >15 fold antibody responses for Arm A: 8; B: 43.5; C: 50.5 (ranges 0-9; 41-46; 9-162, respectively). There was a significant difference in antibody response between Arms A and B (P=0.0001).
    
    Conclusion:
    Allogeneic DPV-001 vaccine administration was tolerable, and >15 fold antibody responses were documented in all but 1 pt. Greatest antibody responses were seen with vaccine/GM-CSF. For pts who may not respond to anti-PD1 due to lack of endogenous anti-tumor response, vaccination with DPV-001 could potentiate checkpoint inhibitors by inducing anti-tumor response. A combination DPV-001 vaccine with anti-PD1 study in advanced NSCLC is pending. NCT01909752, NCI sponsored trial R44 CA121612
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.